Adeno-associated viruses (AAVs) are increasingly being utilized as vectors for gene therapies because of their low immunogenicity and cytotoxicity, high delivery efficacy, and their broad tropism due to the variety of serotypes available . Structurally, AAVs consist of an icosahedral, 60-mer capsid composed of the three viral proteins (VPs) VP1, VP2, and VP3 in an approximate 1:1:10 ratio, respectively . However, recent studies have shown that this stoichiometric ratio may be more varied than once thought and that alterations in this VP ratio during manufacturing can impact product potency . Though each serotype has their own unique VP1, VP2, and VP3 proteins, within a single serotype all the VPs have the same C-terminal region, with the sequence of VP3 contained within that of VP2 and the sequence of VP2 contained within that of VP1 . These capsid proteins have been found to inherit post-translational modifications (PTMs) during production and storage, some of which are reported to impact transduction efficiency and infectivity . Thus, evaluating such critical quality attributes (CQAs) is crucial to ensuring product quality.